ACMG Suggests Doctors Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability

The American College of Medical Genetics and Genomics said today that all breast cancer patients should be evaluated to determine if they should receive germline genetic testing for assessing their inherited risk for the disease. 

Pal clarified in an interview that the statement is not a guideline and doesn’t reflect a change in recommendations. ACMG experts issued the statement to communicate to clinicians the evidence supporting germline genetic testing in breast cancer, and presented information that they should consider when making the decision about which patients to test. 

When deciding which test to order for assessing inherited breast cancer risk, the ACMG urged clinicians to pick a lab that is certified under the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists, and to choose testing that involves sequencing full genes, analyzing deletions and duplications, and detecting known pathogenic and likely pathogenic intronic variants.

Source: https://www.genomeweb.com/molecular-diagnostics/acmg-suggests-docs-evaluate-all-breast-cancer-patients-genetic-risk-test